Connect
MJA
MJA

Pharmaceutical Preparations

Clinical update

The aromatase inhibitors in early breast cancer: who, when, and why?

Ilona C Nordman, Andrew J Spillane and Anne L Hamilton

Med J Aust 2005; 183 (1): 24-27 Free

Letters

Should thyroxine tablets be refrigerated? Have we got it wrong in Australia?

Ovais Siddiqui

Med J Aust 2005; 182 (12): 650

Letters

Weight gain and diabetes with “second-generation” antipsychotic drugs

Andrew Firestone

Med J Aust 2005; 182 (12): 652-653

Editorials

Tailoring access to high cost, genetically targeted drugs

Wayne D Hall, Robyn Ward, Winston S Liauw, Jo-anne E Brien and Christine Y Lu

Med J Aust 2005; 182 (12): 607-608

Medicine and the community

A community-based intervention to reduce antibiotic use for upper respiratory tract infections in regional South Australia

William B Dollman, Vanessa T LeBlanc, Lynette Stevens, Peter J O’Connor and John D Turnidge

Med J Aust 2005; 182 (12): 617-620 Free

Letters

Should thyroxine tablets be refrigerated? Have we got it wrong in Australia?

Jim Stockigt

Med J Aust 2005; 182 (12): 650

Letters

Tramadol and seizures

Ian W Boyd

Med J Aust 2005; 182 (11): 595-596

ADRAC Report

Bisphosphonates and osteonecrosis of the jaw

Patrick M Purcell and Ian W Boyd

Med J Aust 2005; 182 (8): 417-418

Notable cases

Bisphosphonates and avascular necrosis of the jaw: a possible association

Glen Carter, Alastair N Goss and Chris Doecke

Med J Aust 2005; 182 (8): 413-415 Free

Book review

Psychotropics, A to Z

Gordon F S Johnson

Med J Aust 2005; 183 (7):

Book reviews

Controversial scientist

Roy MacLeod

Med J Aust 2005; 183 (1):

Conference report

Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology

Richard O Day, Donald J Birkett, John Miners, David A Henry, Gillian M Shenfield and J Paul Seale

Med J Aust 2005; 182 (7): 322-323

Research

Adverse drug reactions in older Australians, 1981–2002

Christel L Burgess, C D’Arcy J Holman and Anthony G Satti

Med J Aust 2005; 182 (6): 267-270 Free

New Drugs, Old Drugs

Lipid-modifying drugs

Leon A Simons and David R Sullivan

Med J Aust 2005; 182 (6): 286-289 Free

Letters

Barriers to diagnosing and managing heart failure in primary care

Alexandra A Bennett, Jo-anne E Brien and Peter S Macdonald

Med J Aust 2005; 182 (6): 309

Correction

Correction: Bilateral acute angle closure caused by supraciliary effusions associated with venlafaxine intake

Maria Hannah Pia de Guzman, Sureka Thiagalingam, Poh Yan Ong and Ivan Goldberg

Med J Aust 2005; 182 (6): 312

Editorials

COX-2 inhibitors: exemplars of the drug-safety conundrum

Mark R Nelson, Andrew M Tonkin, Flavia M Cicuttini and John J McNeil

Med J Aust 2005; 182 (6): 262-263

Editorials

Managing adverse drug reactions: time to get serious

Elizabeth E Roughead

Med J Aust 2005; 182 (6): 264-265

Lessons from practice

Acute interstitial nephritis secondary to esomeprazole

Nimeshan Geevasinga, Lukas Kairaitis, Gopala K Rangan and Patrick L Coleman

Med J Aust 2005; 182 (5): 235-236 Free

Letters

Inhalation-device polypharmacy in asthma

Vanessa M McDonald and Peter G Gibson

Med J Aust 2005; 182 (5): 250-251

Letters

The direct thrombin inhibitor melagatran/ximelagatran

Luke R Bereznicki, Shane L Jackson and Gregory M Peterson

Med J Aust 2005; 182 (5): 254-255

Matters arising

Withdraw all COX-2-selective drugs

Peter R Mansfield, Agnés I Vitry and James M Wright

Med J Aust 2005; 182 (4): 197

Matters arising

COX-2 selectivity varies across class

Leslie G Cleland and Michael J James

Med J Aust 2005; 182 (4): 197-198

Matters arising

Possible genetic predisposition to cardiac effects

Hari Manev and Radmila M Manev

Med J Aust 2005; 182 (4): 198

Matters arising

Paracetamol should be first-line therapy in osteoarthritis

Richard O Day and Garry G Graham

Med J Aust 2005; 182 (4): 198-199